CpG‐containing oligodeoxynucleotide promotes microglial cell uptake of amyloid β 1–42 peptide by up‐regulating the expression of the G‐protein‐coupled receptor mFPR2

Sadik K., 2003, The increasing burden of Alzheimer disease, Alzheimer Dis. Assoc. Disord., 3, S75, 10.1097/00002093-200307003-00003

10.1097/00005072-199704000-00001

10.1097/00005072-199812000-00006

10.1152/physrev.2001.81.2.741

10.1016/0006-8993(95)01156-0

10.1002/ana.410170310

10.1073/pnas.93.23.13170

10.1006/exnr.1998.6920

10.1002/jlb.65.4.416

10.1002/jlb.65.4.409

10.1212/WNL.38.8.1285

10.1161/01.STR.28.10.1948

10.1385/IR:31:3:165

10.1086/302477

10.1189/jlb.72.4.628

10.1074/jbc.M101031200

10.1096/fj.01-0251com

10.4049/jimmunol.172.11.7078

10.4049/jimmunol.168.1.434

10.1006/nbdi.2002.0517

10.1128/JVI.78.15.7867-7873.2004

10.1016/j.rdc.2004.04.005

10.1046/j.1365-2567.2003.01739.x

10.1084/jem.190.5.741

Le Y., 1999, Utilization of two seven‐transmembrane, G protein‐coupled receptors, formyl peptide receptor‐like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation, J. Immunol., 163, 6777, 10.4049/jimmunol.163.12.6777

10.1093/emboj/17.21.6230

Yi A. K., 1998, CpG motifs in bacterial DNA activate leukocytes through the pH‐dependent generation of reactive oxygen species, J. Immunol., 160, 4755, 10.4049/jimmunol.160.10.4755

Macfarlane D. E., 1998, Antagonism of immunostimulatory CpG‐oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds, J. Immunol., 160, 1122, 10.4049/jimmunol.160.3.1122

10.1146/annurev.immunol.20.100301.064842

10.1126/science.1088469

10.1111/j.1749-6632.2003.tb07478.x

10.1016/S0022-510X(02)00207-1

Pocock J. M., 2002, Activated microglia in Alzheimer's disease and stroke, Ernst Schering Res. Found. Workshop, 39, 105

10.4049/jimmunol.171.10.5482

10.1097/00062752-199901000-00004

10.1016/S0197-4580(00)00124-X

10.4049/jimmunol.168.10.4854

10.2174/1568010023344698

10.1056/NEJM199301073280104

10.1056/NEJM199007263230406

10.1182/blood-2003-08-2674

10.1084/jem.20030162

10.1073/pnas.0400525101

10.1038/416603a

10.1016/S1074-7613(03)00323-6

10.1093/intimm/5.10.1329

10.1038/416603a

10.1111/j.1365-3083.1989.tb01188.x

Pisetsky D. S., 1992, Anti‐DNA antibodies in systemic lupus erythematosus, Rheum. Dis. Clin. North Am., 18, 437, 10.1016/S0889-857X(21)00736-5

10.1016/S0197-0186(01)00040-7

10.1016/S0197-4580(01)00209-3

10.1002/(SICI)1097-4547(19960115)43:2<190::AID-JNR7>3.0.CO;2-B

10.1016/S0896-6273(00)80187-7

10.1038/78682

10.1006/exnr.1997.6738

10.1038/22124

Lombardo J. A., 2003, Amyloid‐beta antibody treatment leads to rapid normalization of plaque‐induced neuritic alterations, J. Neurosci., 23, 10,879, 10.1523/JNEUROSCI.23-34-10879.2003

Wilcock D. M., 2003, Intracranially administered anti‐Aβ antibodies reduce β‐amyloid deposition by mechanisms both independent of and associated with microglial activation, J. Neurosci., 23, 3745, 10.1523/JNEUROSCI.23-09-03745.2003

10.1038/382716a0

10.1038/382685a0

10.3349/ymj.2004.45.Suppl.28

10.1038/sj.gt.3302364